![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: IGLC3 |
Gene summary for IGLC3 |
![]() |
Gene information | Species | Human | Gene symbol | IGLC3 | Gene ID | 3539 |
Gene name | immunoglobulin lambda constant 3 (Kern-Oz+ marker) | |
Gene Alias | IGLC | |
Cytomap | 22q11.22 | |
Gene Type | other | GO ID | GO:0001775 | UniProtAcc | NA |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3539 | IGLC3 | CA_HPV_1 | Human | Cervix | CC | 1.92e-112 | -1.64e+00 | 0.0264 |
3539 | IGLC3 | CA_HPV_2 | Human | Cervix | CC | 2.77e-131 | -1.76e+00 | 0.0391 |
3539 | IGLC3 | CA_HPV_3 | Human | Cervix | CC | 5.14e-117 | -1.72e+00 | 0.0414 |
3539 | IGLC3 | HSIL_HPV_1 | Human | Cervix | HSIL_HPV | 1.06e-87 | -1.65e+00 | 0.0116 |
3539 | IGLC3 | HSIL_HPV_2 | Human | Cervix | HSIL_HPV | 9.16e-89 | -1.50e+00 | 0.0208 |
3539 | IGLC3 | N_HPV_1 | Human | Cervix | N_HPV | 5.67e-115 | -1.65e+00 | 0.0079 |
3539 | IGLC3 | N_HPV_2 | Human | Cervix | N_HPV | 4.10e-122 | -1.73e+00 | -0.0131 |
3539 | IGLC3 | CCI_1 | Human | Cervix | CC | 2.40e-48 | -1.77e+00 | 0.528 |
3539 | IGLC3 | CCI_2 | Human | Cervix | CC | 1.86e-45 | -1.77e+00 | 0.5249 |
3539 | IGLC3 | CCI_3 | Human | Cervix | CC | 1.16e-59 | -1.77e+00 | 0.516 |
3539 | IGLC3 | CCII_1 | Human | Cervix | CC | 3.60e-76 | -1.77e+00 | 0.3249 |
3539 | IGLC3 | Tumor | Human | Cervix | CC | 1.54e-129 | -1.77e+00 | 0.1241 |
3539 | IGLC3 | sample1 | Human | Cervix | CC | 2.00e-61 | -1.75e+00 | 0.0959 |
3539 | IGLC3 | sample3 | Human | Cervix | CC | 2.77e-138 | -1.77e+00 | 0.1387 |
3539 | IGLC3 | H2 | Human | Cervix | HSIL_HPV | 7.07e-108 | -1.57e+00 | 0.0632 |
3539 | IGLC3 | L1 | Human | Cervix | CC | 2.83e-59 | -1.50e+00 | 0.0802 |
3539 | IGLC3 | T1 | Human | Cervix | CC | 3.64e-105 | -1.68e+00 | 0.0918 |
3539 | IGLC3 | T2 | Human | Cervix | CC | 4.38e-40 | -1.72e+00 | 0.0709 |
3539 | IGLC3 | T3 | Human | Cervix | CC | 8.22e-128 | -1.76e+00 | 0.1389 |
3539 | IGLC3 | HTA11_3410_2000001011 | Human | Colorectum | AD | 6.80e-04 | 2.31e-01 | 0.0155 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00027644 | Cervix | CC | immune response-regulating signaling pathway | 97/2311 | 468/18723 | 1.49e-07 | 7.07e-06 | 97 |
GO:00022533 | Cervix | CC | activation of immune response | 72/2311 | 375/18723 | 8.26e-05 | 1.11e-03 | 72 |
GO:0002768 | Cervix | CC | immune response-regulating cell surface receptor signaling pathway | 59/2311 | 315/18723 | 6.64e-04 | 6.11e-03 | 59 |
GO:00026967 | Cervix | CC | positive regulation of leukocyte activation | 72/2311 | 409/18723 | 1.13e-03 | 9.31e-03 | 72 |
GO:00512516 | Cervix | CC | positive regulation of lymphocyte activation | 65/2311 | 362/18723 | 1.15e-03 | 9.39e-03 | 65 |
GO:00508676 | Cervix | CC | positive regulation of cell activation | 73/2311 | 420/18723 | 1.50e-03 | 1.16e-02 | 73 |
GO:00024603 | Cervix | CC | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 62/2311 | 356/18723 | 3.09e-03 | 2.03e-02 | 62 |
GO:0002443 | Cervix | CC | leukocyte mediated immunity | 73/2311 | 440/18723 | 5.01e-03 | 2.98e-02 | 73 |
GO:0006909 | Cervix | CC | phagocytosis | 53/2311 | 308/18723 | 7.49e-03 | 4.01e-02 | 53 |
GO:00069597 | Cervix | CC | humoral immune response | 54/2311 | 317/18723 | 8.57e-03 | 4.42e-02 | 54 |
GO:00103243 | Cervix | CC | membrane invagination | 28/2311 | 144/18723 | 9.50e-03 | 4.72e-02 | 28 |
GO:000695912 | Cervix | HSIL_HPV | humoral immune response | 39/737 | 317/18723 | 2.88e-10 | 7.02e-08 | 39 |
GO:000269611 | Cervix | HSIL_HPV | positive regulation of leukocyte activation | 44/737 | 409/18723 | 1.58e-09 | 3.04e-07 | 44 |
GO:005086711 | Cervix | HSIL_HPV | positive regulation of cell activation | 44/737 | 420/18723 | 3.59e-09 | 5.76e-07 | 44 |
GO:005125112 | Cervix | HSIL_HPV | positive regulation of lymphocyte activation | 40/737 | 362/18723 | 4.11e-09 | 6.38e-07 | 40 |
GO:000225312 | Cervix | HSIL_HPV | activation of immune response | 40/737 | 375/18723 | 1.12e-08 | 1.30e-06 | 40 |
GO:000276411 | Cervix | HSIL_HPV | immune response-regulating signaling pathway | 46/737 | 468/18723 | 1.17e-08 | 1.30e-06 | 46 |
GO:00160643 | Cervix | HSIL_HPV | immunoglobulin mediated immune response | 27/737 | 207/18723 | 4.74e-08 | 3.59e-06 | 27 |
GO:00197243 | Cervix | HSIL_HPV | B cell mediated immunity | 27/737 | 210/18723 | 6.42e-08 | 4.49e-06 | 27 |
GO:000246011 | Cervix | HSIL_HPV | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 37/737 | 356/18723 | 7.84e-08 | 5.32e-06 | 37 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IGLC3 | SNV | Missense_Mutation | novel | c.130N>A | p.Ala44Glu | p.A44E | IG_C_gene | possibly_damaging(0.831) | TCGA-C5-A902-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | ||
IGLC3 | SNV | Missense_Mutation | rs775684254 | c.198N>A | p.Ala67Thr | p.A67T | IG_C_gene | benign(0.071) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
IGLC3 | SNV | Missense_Mutation | rs781722973 | c.171N>T | p.Pro58Ser | p.P58S | IG_C_gene | possibly_damaging(0.785) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
IGLC3 | SNV | Missense_Mutation | novel | c.98C>A | p.Phe33Leu | p.F33L | IG_C_gene | probably_damaging(0.997) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
IGLC3 | SNV | Missense_Mutation | novel | c.103N>T | p.Pro35Leu | p.P35L | IG_C_gene | possibly_damaging(0.902) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
IGLC3 | SNV | Missense_Mutation | novel | c.265N>C | p.Val89Ala | p.V89A | IG_C_gene | probably_damaging(0.963) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
IGLC3 | SNV | Missense_Mutation | novel | c.201N>T | p.Ala68Ser | p.A68S | IG_C_gene | possibly_damaging(0.905) | TCGA-69-8255-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
IGLC3 | SNV | Missense_Mutation | novel | c.256N>T | p.Ser86Ile | p.S86I | IG_C_gene | possibly_damaging(0.88) | TCGA-78-7155-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | PD | ||
IGLC3 | SNV | Missense_Mutation | novel | c.201N>T | p.Ala68Ser | p.A68S | IG_C_gene | possibly_damaging(0.905) | TCGA-56-8307-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
IGLC3 | SNV | Missense_Mutation | rs758947730 | c.285N>A | p.Val96Met | p.V96M | IG_C_gene | benign(0.17) | TCGA-94-A4VJ-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |